Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab Prospective Cohort in Prurigo Nodularis and Atopic Dermatitis
ChiCTR2300068229Phase 4Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of dupilumab in prurigo nodularis (PN) and atopic dermatitis (AD) (3 arms), sponsored by Peking University First Hospital. Primary endpoint: WI-NRS response rate at week 12. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
03
Conditions
prurigo nodularis (PN)atopic dermatitis (AD)
Beyond the preview
Go deeper on ChiCTR2300068229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068229.